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iJ&elfves. TM study attempted lo dctenolno Lhe opthal 
intwsity of aoticoagalaot therapy in patients after myocardial 
hluwctioa. 
Bac&mand. Treatment with oral anticoagalaot therapy entailr 
a delicate babmce between over- (risk of Meediagl aad under. 
aotkoaplatlon (risk of thmmboemboll). The opthnal late&y 
required to prevent the occomnce or either event (bleed& or 
thromboembolic) is not known. 
hfdtais. A method wa6 used to determine the optbaal loteasily 
of antkoagalaot therapy by caktdatiap iacidence mtes for either 
event assocb&d with a specific iateraatbmal n0imaLe.d ratio. 
The oomerator ineluded events occaniag at gives interaalioaal 
oo~~~alized mtios, and the denominator comprised the total 
olMervetioo the. 
f&St&. The study popalalioll in&&d 3,4ou myoeardial in- 
fiwctioo pnlknts enmlled in the AsPECf (Anti&t.9 in the 
Secondary Preveotioa of Events ia Comaary Thrombosis) trial. 
Total tmatateat was 6,918 patient-years. Major bleeding occarrod 
in 57 palienls (O.t?/lOO patient-yearn), sod tbmmlnwmbolic com- 
plications In 397 (5.7/100 patient-years). The incidence al the 
---. 
Findings of the three most recently performed trials following 
myocardial infarction demonstrated that intensive anticoagu- 
lant therapy reduced the rate of reinfarction by 34% to S5%, 
stroke by 40% to 55% and total mortality by 10% to 26% 
(l-3). In these investigations, a high quality of anticoagulation 
was achieved, because 63% to 74% of the prothrombin time 
measurements were withill the therapeutic international nor- 
malized ratio range between 2.5 and 5.0. 
Although the investigations demonstrated beneficial ef- 
feCtS of aUtiCOagUiatIt treatment in IUymrdidl infarCtiOII 
- -  - - _ I - _ . ~ .  .  . . 1 . . -  
combined oatcome (bleeding or -cqumm) 
with inlernatioaal normalized ratio u2 was f&64@il patieatgan 
(283 e v e n t s  in 3,559 patlea&yearB), with 
ratios hehwea 2 and 3, 3.9/100 patieat 
patlua~-yearu); 3Ylee p d e o b y u l m  cn evelltr lo 1,77J plltleal- 
yellI%) for In terMWalnormauzadlatlaE~3aBd1; 
6400 patiee@eam (37 eve& ia SCQ pot&ut.yeam) for bl&na- 
t&WlOarmslbedraWbelwaeo4andJ;aIul7.7/11~. 
years (14 LwRtll in 182 p n u e n t . y e a r s )  for ivlteraationld normal- 
optinlal llltensuy ti !ang-krol ratlonsglult hwkm 
dialinuwcuorlpatiolltsueshetawen2.0andI0lotermlthnllll 
normalized ratb 4th a tread to suggest aa optimal in&a&y of 
3.0 to 4.0. 
(j Am ciln cmn%iol 199&27:13494s) 
---.. _.. 
survivors, these trials have not established the optimal 
intensity of anticoagulant therapy for two major reasons. 
Fiist, ibc intensity of anticoagulant therapy actually 
achieved was not taken into account, and, second, the t8rgCt 
level of an:icoJgulation was chosen arbitrat ily. For the same 
reasons, randomized trials conducted to compare two intcn- 
sities of oral anticoagulant therapy offered little information 
on the optimal intensity of anticoagulant therapy (4). There- 
fore, it is not known what intensity of anticoagulant therapy 
offers the optimal benefit-risk ratio, that is, the optimal 
balance between prevention of thromboembolic events and 
Heeding complications. 
To determine this optimal intensity of anticoagulant ther- 
apy, we quantitatively evaluated the oecunence of hemor- 
rhagic as well as arterial thromboembolic complications with 
respect to the international normalized ratio level preceding 
the event, thereby enabling the calculation of international 
normalized ratio-vpecilic incidence event rates. The study 
population comprised 3,404 myocardial intarction patients 
random+d to anticoagulant therapy or placebo. 
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Methods cular event leading to death within 24 h was considered to be 
htkntr The ASP&T (Anlicoagulunts in the Secondary 
caused by intracranial F.leeding unless the Rndings on corn 
Prevention of Events in Coronary Thrombosis) subjects com- 
puted axial tomography scanning indicated otherwise; in all 
prised the study group. This trial has been described in &tail 
other instances, the diagnosis of an intracranial hemorrhage 
elsewhere (3.5). la short, ASPECT was a randomized, double- 
had IO be confirmed by findings on CAT scan (1 l), or 3) led to 
blind, placebocontrolled, multicenter, clinical trial that com- 
hospital admission for treatment of bleeding (hospital admis- 
pared anticoagulant, therapy with placebo on mortality dnd 
sion for diagnostic purposes only was not considered a crite- 
cardiiascular events in myocardial infarction patients. This 
rion for major bleeding). 
trial demonstrated that anticoagulant therapv targeted at 
Thromboembolic complications included 1) instantaneous 
international normalized ratio 28 to 4.8 reduced the rates of 
or sudden death occurring within I h after onset of symptoms; 
recurrent myocardial infarction by 33% and intracranial events 
(2) recurrent myocardinl infarction documented by at least two 
by 40%. The premt analysis was planned as an ancillary one 
of the fnllowing (12,13): a) history of chest discomfort of at 
least 30 min duration; b) serial enzyme pttem typical for 
before study termi,iauon. 
Hospital survivors of acute myocardial iGrrtion were 
myocsrdial infarction qvith at least one cardiac enzyme excecd- 
ing twice the upper limit of normal: or c) the development of 
screened for eligibility just before hospital dirharqr. After new Q-waves Ilisting X03 s or of Q-wave equivalent 
giving informed consent, patients were randomly assigned to [H >0.03 s in V, and R/S >l in Vz]j on the standard 1Zlead 
trea!ment with oral anticoagulant therapy or matching pla- electrocardiogram (ECG); myocardial infarction was also di- 
ce& From September 1, !9S6 until December 31, lWl,3,404 agnosed when death occurred within 28 days after hospitalixa- 
patients entered the trial. Their mean age was 61 years, 20% tion for recurrent myocardial irdarction; 3) cerebral infarction, 
were women (mean age 65 years), fewer than 8% had diaberes, 
25% had been treated with thrombolytics, arrd 95% of the 
classified according to internationally accepted criteria and 
diagnosed on the basis of the CAT-scan findings (11); and 
patients were in Killip class 1 or II during hospitalization. 4) other arterial thromboembolic complications. 
Fewer than 2% of the patients had undergone a revasculariza- Information on clinical events was obtained directly from 
tion before study entry, and Y% had su5ered a previous the patients when they visited the anticoagulant clinic or from 
myosardial infarction. Medication at hospital discharge in- their general practitioners. In case. of hospitalization, addi- 
chrded beta-adrenergic blocking drugs in 50% and angiotensin- tional information was retrieved from the hospital records, The 
mnverting enzyme inhibitors in 9%. Because the present diagnosis and classification of clinical events were established 
analysis considered only the period under trial medication, the by the Mortality and Morbidity Classification Committee of 
mean follow-up per patient was 2.1 years. the ASPECT trial, who independently reviewed the clinical 
Oral saticuagolatkn and dose n&Mment. The target course of each case on the basis of a revic‘!; t&r a standardized 
anticoagulant range was 2.8 to 4.8 international normalized patient report before study termination. ‘lne committee mem- 
ratio (6-9). Individual dose adjustments were guided by the bers were unaware of treatment assignment and were not 
prothrombin time measurements obtained at regular intervals informed of actual prothrombin time measurements. 
at I of the I9 participating anticoagulant clinics. Anticoagulant Assessment d nptitnal intensity. Incidence rates were cal- 
treatment consisted of phenprocoumon, acenocoumarol or culated for different achieved intensities of anticoagulant 
matching placebo tablets. Double-blinding was maintained at therapy (4). Intervals of 1.0 international normalized ratio 
the anticoagulant clinics by use of a computerized dosage were used. As the lowest reference interval, we used intema- 
algorithm that automatically converted prothrombin times to tional normalized ratio <2, which includes the patient-time of 
sham values within therapeutic range in placebo-treated pa- all patients on placebo and actual measurements of interna- 
tients. tional normalized ratio <2 in patients receiving anticoagulant 
At each follow-up visit to the anticoagulant clinic, a short drugs (5%). This reference category represents absence of 
history was taken, and a blaod sample was drawn for determi. treatment. Only those international normalized ratio measure- 
nation of the i’nrombotest, a modified prothrombin time test merits that were obtained during the trial medication period 
(!a). Patients were seen at the initial (randomization) visit and were considered. The optimal intensity of anticoagulant ther- 
n- a weekly basis thereafter until the prothrombin time spy will lie at the level at which the incidence of bleeding or 
measurements were within the specified target range. The thromboemboli is lowest, that is. where the incidence of 
interval between visits was subsequently prolonged up to a complications, whatever their type, is lowest. This approach 
maximum period of v weeb. Patients requiring frequent has been explained in detail previously (4). 
dosage adjustment!, were iecn more regularly. At the end of Numerator dater events. The numerator of the intema- 
trial in June lW2. trial medication was discontinued in all tional normalized ratiospeci!ic incidence rate was compoed 
patients. of even& (bleeding or thrombo:mbolism) occurring at a given 
lkhitkn of clinical events. The following clinical events intertihational normalized ,ratio intensity. If the international 
wert conridered: major bleeding or thromboembolii cnmpti- normatired ratio measurement for the date of event was not 
Cations. Bleeding was considered major if it 1) led to death, available, the last international normalixed ratiomeasurement 
2) was clinically stupected or proven intracranial (cerebrovas- obtained within a maximum period of 28 days bclore the event 
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Tabte i. Selected Demographic, ilaseline und Randombtion 
Characteristics 
No. of patients (%) 
Mean age, years (SD) 
Gender (9%) 
- 
Andorirgulant Plwlxr Total 
1.7fKl(luo) I.m4(Ioo) 3.404 (loo) 
61 (II) 61(11) hl(lll 
Tab& L Ineidencc of Mnjor Bkediig During Follav-Up 
Anlio~rnt 
(n = uoll) (II:%, Total 
I,37o(lll) 1,350 (79) 2,270 (80) 
33u(I9) 354 (tl) h@ (20) 
PhenpICXOUIM~n 9x1 (SS) 93s (S5) I,nhS (S5) 
Accnocoumarol 770 (45) 7h9 (45) l,W(45) 
Mean SAP. mm Il# (SD) llY(lht 119(lfl) Il9(l6) 
-- ----_-__~--_I 
SBP ~y41c hhwl ptesurc il l hwqilal discharge. 
Number of patknt-yeam 3.4&l 3#it!Il 6,918 
lnlmuankl bkedfng 14 1 15 
Fatal 7 0 7 
Nonfatal 1 I I8 
ExtMnwial b!ding 37 5 42 
F&d 2 0 2 
Nwfaul 3s 5 40 
Tutid major hhwdq’ SI (I.C1ll~l py) h(ll.UII* py) Sf (0.fwI) pr) 
~-~_-_- 
‘Inlrarrani~l or rxlrwr;tninl hkcding, whichever occurred first. py = pknt- 
ycan. 
was taken from the hospital reL%rds. Inlemational normalized 
ratio measurements were considered misshig iu all other 
instances. Patients who were treated with placeh) were in- 
cluded in the analysis because their achieved international 
normalized ratio intensity corresponding to “hick” of antico- 
agulation is of course known and corresponds to an intema- 
tional normalized ratio of 1 at the time of pn event as well as 
at all other times. In a subsequent, stricter analysis, we only 
included events for which an international normalized ratio 
measurement obtained no more than 3 days before the event 
was available, whereas all others wale considered missing 
(except for the placebo patients). 
value (below or ahwc MJ yean of age and 120 mm lig, 
rcspectivcly). The incidence rate ratim obtained from the 
model may be viewed as relative risks, that is, the risk for an 
event relative to the reference risk factor category controlling 
for the other risk factors. The 95% confidence mtervais were 
obtained from the Poisson distribution. 
Results 
Patients were censored when dn event was reached after 
cessation of trial medication or at the end of follow-up, on 
June 30, 1992, whichever occurred first. In case patients 
experienced more than one event, only the lirst was consid- 
ered. Four patients with major bleeding from an invasive 
interventional procedure during hospitalization were not in- 
cluded in the analysis. 
A total of 1.7OU patients were randomized to anticoagulant 
therapy (with 3.430 patient-years of follow-up), and 1,704 to 
placebo (with 3,4@ patient-years of follow-up); 55% of the 
patients received phenprmumon, asd 45% acenocoumarol 
(Table 1). 
Denominator da@ international normalized ratiu-time. 
The denominator of the international normalized ratio-specific 
incidence rate comprised the sum of patient-days within spe 
cific international normalized ratio intervals (4). In order IO 
calculate the time each patient was within an international 
normalized ratio-specific range, we assumed a linear interpo- 
lation between adjacent international normalized ratio mea- 
surements (5). In addition, ;n case the intcn::! between two 
consecutive international normalized ratio measurements ex- 
ceeded 56 days, this time period was not included in :he 
present analysis, because a linear change over this long period 
of time hcomes unrealistic. Patients who used placeho were 
considered to have international normalized ratio metiure- 
merits below 2 during the total period of folknv-up. 
The incidence of major bleeding is shown in Table 2. 
Fifty-seven cases of major bleeding (O.g/lOt) patient-years) 
occurred, 51 in the anticoagulant (l.S/lOO patient-years) and 6 
in the placebo group (O.UlOO patient-years). This resulta in a 
relative risk for major bleeding of 8.6 with a 95% confidence 
interval of 3.7 to 20.1. Fatal bleeding (nine patients) was 
observed only in the anticoagulated group (0.3/100 patient- 
years). The most frequent sites of major extracranial bleeding 
were the gastrointestinal tract (?6 with anticoagulation and 2 
with placebo) and muscular hem stoma in 10 of the anticoag- 
uhtted group. 
P&sod mgression analysis. The relative risk of bleeding 
or thromboembolic events associated with international nor- 
malized ratio-spcific intervals after adjustment for age. sex. 
type of coumarin congener and ,blood pressure was calculated 
with Poisson regression analysis (14). The Poissoii was used to 
model incidence rates for grouped data. Age and systolic blood 
pressure. measured during hospitalirAon for the index myu 
cardial infarction, were categorized on the basis of the median 
The incidence of thromboembolic events is presented in 
Table 3. A total of 397 thromboembolic complications (.5.7/100 
patient-yean) occurred, of which 118 were, fatal. One hundred 
twenty-seven thrombwmbolic events (3.71100 patient-years) 
were ohscnled in the anticoagulation group, and 270 with 
pidcebo (7.7/100 patient-years). resulting in a relative risk for 
major thromboemholic complications of 0.48 with a 95% 
confidence interval of 0.39 to 0.59. The major thromboemboli 
events included sudden death (69 patients), recurrent myocar- 
dial infarction (293 patients) and cerebrdl infarction (34 pa 
tients). 
International normalized ratio measurements obtained at 
hospital admission or within 3 days before the occurrence of 
major bleeding were available in 42 caws (6 of 6 placebo and 
36 of 51 rticoagulation patients) and in 55 patients (6 of 6 
A7AR El‘ Al. 
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placebo .rnd JY of 51 an:icoagul~ltion patients) withiu a time 
frame of 28 days. lntcrnational normaliicd r&i,) measure- 
ments within 3 dap from thromboemholic complicatron were 
obtained in 2Y4 patients (270 of 270 placetm and 34 of 127 
anncoagul.bn pattcnts) and cithin ;-‘X days m 37; patients 
(30 of 270 placrho ;md )05 of 127 rnticoagulatior palients). 
Ths totA numhr lrl patient.ycarswithin mt~~~a~~o:~al normal- 
ized ratio-specific intervals for the combined ever: (bleeding 
or thmm~rcmholi) *:etz 3.55Y patient-years (;9temational 
ntrrmalized ratto s 2). UK pdlicr8t.?esr\ (internaliw~~! normal- 
tred ratio 2 IO 3). l,7?5 patient-years (intcrnati:~nzl nc,rmali& 
raticr .J IO 4). St4 patient-years (international normalited ratto 
4 to 5) and )H? patient-year. (international norrnmalired ratio 
>5) for international normalized ratio measurements obtained 
uithin 3 or 2X days from rhc cvcnt. 
Intcrnatamal normalilcd rdtttt-\pcc:ltic ncrdcnce rates 
bed on meii%Jremenl\ trhlantcd Hllhlrt 2s ddv\ 01 m;ljor 
hlceding and rhrrrmhrrmholic compltcatnrn arc presented in 
Figure I and in ‘fat&z 4. l?ic intcmdtwal ~wrmahul ratio- 
‘Ii&k 4. Incrdencc of tvcnlr Withut litc Specitic Inlernationrt 
Ncm~~~hml Ham, Inleivels .-__ .,-. -LI-_--- 
INH I,C”l~ Pdliclll.YEilrb Inclllcncc Rule . . . -._..._ . ._ . _-^-._. .I__ -_..-I- - - -. _ . _ --- 
Ilcnrwrktgir 
. ..-_... -----~.-.-.--- _..- -..--.- _-_- -- 
3 II 3,NU IWlWlpy 
Z-3 s 157 11.7110JUpy 
?-4 Ih I,XII o.YXmpy 
4-s I4 576 2.4/lwpy 
.A5 I? 151 7.91wpy 
I_. 
Thmmhwmbolic 
- -_--.--- .-.. -c__ 
\ 
:-I 
32 WY x.il/llnlpy 
27 771 .I.i/lM)py 
3-4 II I .hSJ ? ?llHlpy 
4 i ?.I vx 4.4, Iwpy 
.5 , I?0 I.hWl)py 
--_--. _ .._ - .---.-- 
Iir*nwrrh.~gir or ‘~hr~~mlxwmMe 
____--- 
2 x3 .i,:.SY X.llWGpy 
z-3 f! x3x 3.w1wpq 
3-4 Sl 1.775 Wl(K)w 
.ls 17 .%I h.h/lluJp 
.s I4 IX2 7.7mpy 
I-- 
specific incidence rate of Needing *vas lowest, 0.2 per I00 
patient-years (f! events in 3,603 patient-years), at anticoagulant 
intensit;es less than 2 international normalized ratio and was 
highest, 7.Y per 100 patient-years (I2 events in I51 patient- 
years). at anriccqulant intensities exceeding the value of 5. On 
the Ythcr hand, the incidence of thromboembolic complica- 
tions w:s highctt, X.0 per IIHf patient-yean (X? events in 3.5OY 
patient-yean), fur anticr,agulant intensities less than 2 inter- 
national normalized ratio and was lowest, 1.4/)UO patient-years 
(2 rvonta in 126 patient-years) for international normalized 
ralio inlenaities exceeding !he vdluc of fi. 
The uplimnl nnlic~ulao~ inkasi?y. The incidence of the 
combined outcome (bleeding or thromboembnlic complica- 
tion+) occurred in 423 cases (6.1/100 patient-years). The inci- 
dencc was Imvest, 3.2/l(K) patient-years (57 events in 1.775 
patient-years). at ,nternational normalized ratio values be- 
tvieen 3 dnd 4.. Im:rnalional normalized ratio-specitic inci- 
dencc ratec uith curropnnding YSci. confidence intcrvalu, 
hard on international normaliucd ratio measurements oh- 
tamed within 28 days from event, are presented in Figure 2. for 
the comhincd events of hlceding as we!1 as thromboemholi. 
‘I’hr inciderw of complications wdb hikhcst at international 
mmnalized ratio values below 2 and ahove 5. The intensity at 
uhich th*! intematioml ncrrmalized ratio-qrccific incidence 
r.ttcs ot 11~ curve A ltmrst is the optimal intersity: between 3 
,rnd 4 InkrndlHInal mnmalircd ralio. Sini!l:u rehullb were 
trhtamcd when thr analyus SKIS repeated ,!or intemattonal 
normalucd ratm nw~wrcmrnt~ c&taincd ui:hin 3 dap frclm 
rhc cncnr 
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Figure 2. lnlcrnational nulmalizcd raGa (Inr)-specific incidence rates 
for the cambmed event (bleeding or thromboemboiic complications). 
Dashed line% indicate YSB confidence interval. 
ciated with age* sex, systolic Mood pressure at discharge and 
type of coumarin congener; results, after controlling for 
achieved international normalize 1 ratio intensities, are pre- 
sented in Table 5. Significant predictors for major bleeding or 
thromboemboli included higher systolic blood pressure and 
more advanced age. The risk of bleeding was higher in women. 
Discussion 
The optimal iotensiry, the intensity of anticoagulation at 
wh&h the incidence of hemorrhages as well as thromboemb~~- 
lism was lowest, appe~: :d to be located between mtemational 
normalized ratio 2.0 and 4.0, with a trend to suggest an optimal 
intensity behveen 3.0 and 4.0 international normalized ratios. 
In this range, the risk of bleeding was relatively low, amountin,: 
to 5 major bleeding complications per i.ouO treatment-years, 
Table 5. Multivariate &X$i$ of Other Risk Factors for 
Hemorrhagic and Thrombocmbolir Complications’ 
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while the reduction in thromboembolic complicationa, relative 
to international normalized ratio intenaitic below 2, was 70%. 
Such a narrow range for optimal anticoagulation could be 
achieved in only approximately 20% of patient-years in this 
study, although the quality of long-term anticoagulant therapy 
achievable in the Netherlandson a population basis is pro&My 
unique. The broader range (international normal&d ratio 2.0 
to 4.0) could be attained in 75% of patient-years and was 
almost as etfective. Such iev*:ls may be more readily achievable 
in general. 
Intensity of aatlcorpulntion end rtrk al bledhg, The risk 
of bleeding associated with anticoagulant therapy in patients 
with as well as without coronary h! art disease is well rwog- 
nixed and has led to the conduct ois~veral trials that compared 
the efficacy of different intensities of oral anticoagulant therapy 
(15-17). So far, however, these trials have been unable to 
provide the “true” optimal anticoagulant intensity. The msin 
reason, ofcourse, is that achieved anticoagulant intensity is not 
constant and will invariably fluctuate around the prespecitled 
target level hinging on particular characteriaies of the patient 
under treatment as well as on extraneous features related to 
the administration and monitoring of the therapy. 
Given the acknowledged relation between incidence of 
bleediug complications and high anticoagulant intensities (IS- 
22), it is surprising that few attempts have been made to 
quantify this association. In one recent population study (23) in 
which the achieved intensity of anticoaguhmt therapy was 
analyzed in 6,814 patients, a 42% increase in the risk of major 
bleeding was reported for every rise of I .O in the interrlational 
normalized ratio. In another recent analysis, a nested case- 
control study of 565 patients starting outpatient therapy with 
warfatin by Lndefcid et al. (20). the odds rario for major 
bleeding increased with increasing prothrombin time to am- 
rroi ratios. In the present anrtysis, the risk of major bieeding 
i Icreased gradually with elevation in ihe intensity of anticoag- 
ulation achieved. The risk was increased 80% when intema- 
tionai normalized ratio intensities were between 4 and 5 as 
compared to int-nsities below 2 international normalized ratio, 
v,hile the risk was increased almost fivefold when international 
normalized ratio intensity exceeded 5. 
letcn~ity of aatkoagulation ned &k of tbmdoembotk 
compllcattoas. Although it seems reasonable to assume an 
increased risk of thromboemboiic events with less intense 
anticoagulation, this conclusion cannot easily be extracted 
from the literature. In addition to the previously mentioned 
mcthodologicai issues. the relatively small size of some studies 
is another limiting factor. Evidence for strong ekcts of 
anticoagulant therapy on thromboembolic complications were 
obtained in the three most recently conducted placebo- 
controlled trials: the Sixty-Plus (I). WARIS (2) and ASPECT 
(3). The intensity of treatment in these was characterized by a 
prothrombin time prolongation of 2.5 to 5.0 intematiJnal 
norm#zed ratio. These trials convincingly demonstrated thnt 
a substantial reduction in myocardial infarctions and cerebro- 
varuiar events can be achieved with this type of therapy. 
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~l@lhs ofour study. A drawhack of our analysis is thaI 
we were uniihk ki ohlain intcmstioni:l nurmali~eJ ratio mea- 
surcmenb at the time of Ihe event in every inslance. in 
pa&u$r for the thromboembolic evcnls. Prothromhin ltmc 
measurement at the moment of the evcnl was nol rpecifirally 
required by the study protocol and, therefore, was nol alwiiys 
reported by the investigator. In bleeding patients on oral 
anticoagulant therapy, an international normalized ratio mea- 
surement will bk performed far more often than in a patient 
with a myocardial infarction. This is unfortunate hut alTects 
only the power of the study, not the validity, because it is not 
conceivable that the decision to perform or not perform an 
international normalized ratio in a pAcnt with myocardial 
infarction is dependent on his or her (known) international 
normalized ratio. ft should be noted that douhle-hlinding WOLF 
still maintained at the time of hospital admission. When we 
restricted the analysis to events with an international normal- 
&d ratio at or shortly before (~3 days) the event, interna- 
tional normalized ratio dili1 were available in only about 34% 
of the patients taking anticoagulants (and all placebo patients). 
When a less stringent criterion was used, and international 
normalized ratio measurements up IO 28 days before the event 
were accepted as representing the international normalized 
ratin at the event, we had information on 87% of the antico- 
agulation patients (and again in all pla~cbo patients). Although 
both analysL3 are obviously suboptima:, ;hey lead to the same 
reMIt of a nadir of event\ al international normalized ratio 
values betwxr! 2 dttd 4. Although these findings will need to be 
ccnlirmed m larger series, these first analyses of the achieved 
intensity of anticoagulant therapy in myocardial infarction 
patients point to an optimal mtcnsity of 2 lo 4 intcrnatainal 
normalized ratio. with a trend to suggest that the optimum 
intensity lies between 3 and 4 international normalized ratlo. 
In this analysis, the optimal intensity of anticoaguiant 
therapy was defined as the level at which the incidencT of the 
sum of hleeding or emholic complications wab IOWCSI, and they 
wcrc equally considered. We r :alizc that this is not always 
realistic. and it is dependent on the xverity of the actual 
complication, cardiac or neuralogic. The actual rate of cmbolic 
as well as hemorrhagic complications is therefore given here. 
Prediction of events. In line with findings reported by 
others, the current analysis confirmed the independent contri- 
bution of higher systolic blood pressure to increzed bleeding 
tendency during anticoagulation therapy (24). High Mood 
pressure was also associated with increased thromboembolic 
complications. Our results confirm a recent obscwalion of a 
higher hkxding incidence iu elderly and female patients (2% 
2S). ln contrast to findings of another analysis that employed 
the same quantitative approach as currenl’y described (23). we 
were unable to Lu,nRrm the associa:ion of the uw cjf accntuou- 
marol with increased bleeding tendency. 
Coacluriioak In conclusion, th: c1ptim.d therapeutic range 
for kxl~tcrrn oral anticoagulant th :raPy in mytrardial infarc- 
tion pattints has been a F*ttcr of irltenw debate for more than 
30 yean (4). Findings in this lari ,e cohort provide a quanti- 
tative basis to locate the optima therap&c anticoagulant 
intensity within the inlcrnational normalized ratio range of 2.0 
and 4.0, assuming that equal weights are given to hemorrhagic 
and thromboembolic complications, with a trend to suggest an 
optimal intensity of 3.0 to 4.0. In this range, somewhat lower 
than the targeted anticoagulant inlcnsity in the most recent 
secondary prevention trials (27). the incidence of major bleed- 
ing during long-term anticoagulant (her&y is relatively small, 
and a substantial reduction in the rate of thromboembolic 
events is achieved. 
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